EZH1 Inhibitors
1 drugsAbout EZH1
EZH1 (Enhancer of Zeste Homolog 1) is a histone methyltransferase involved in DNA packaging and gene regulation. It can maintain function even when EZH2 is inhibited, making it relevant for combination therapies. EZH1's activity impacts cancer development and progression through epigenetic regulation.
EZH1 is targeted to restore normal gene expression patterns and potentially halt tumor growth. There is currently no genetic evidence directly linking EZH1 mutations to specific diseases. Modulating EZH1 activity could have therapeutic benefits in certain cancers.
EZH1 is targeted by one FDA-approved drug, TAZVERIK, a small molecule developed by EPIZYME INC for oncology indications. TAZVERIK was first approved in 2020.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Follicular Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 53% completion.
Top EZH1 Drugs
EPIZYME INC is the only company with an approved drug targeting EZH1.
The market is not yet saturated, presenting an opportunity for new entrants with differentiated EZH1 inhibitors.
EZH1 Clinical Trials 50 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 30 | 7 | 10 | 12 | 41% |
| Phase 2 | 19 | 7 | 5 | 6 | 58% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 57 clinical trials targeting EZH1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities